U.S. Sex Reassignment Hormone Therapy Market to Grow with Increasing Awareness and Access

The U.S. sex reassignment hormone therapy market size accounted for USD 1.3 billion in 2025 and is predicted to increase from USD 1.39 billion in 2026 to approximately USD 2.61 billion by 2035, expanding at a CAGR of 7.2% from 2026 to 2035. Increasing demand for sex reassignment hormone therapy due to growing awareness, increasingly accessible care, targeted physical transition, and increased visibility.

What is Sex Reassignment Hormone Therapy?

Sex reassignment therapy includes the healthcare technology and interventions associated with gender transitioning, enabling persons to align their physical bodies with their gender, which may differ from the sex allocated to them at the time of birth. This therapy involves different options like hormone therapy, voice therapy, puberty blockers, and various surgical technologies such as chest and genital surgeries. Transgender individuals undergo these therapies to lessen gender dysphoria; not all transgender individuals choose to pursue healthcare interventions, and such decisions are intensely personal.

Recent Advancements in Hormone Replacement Therapy:

Recent advancements in hormone replacement therapy are set to transform medical care. There have been few significant developments in the administration of testosterone or oestrogen in over 20 years. Gender-affirming hormone treatment (GAHT) aligns transgender women’s hormone profiles with their gender identity, lessening gender dysphoria by making feminizing changes. The efficiency of GAHT on musculoskeletal health, predominantly bone mineral density (BMD), needs continuing evaluation. Individuals undergo gender-affirming hormone therapy to improve the alignment of their outer appearance with their gender identity. GAHT can be a stand-alone intervention or combined with surgical technology.

In U.S. Adults by Self-Identified Gender Identity

Market Segmentation Overview

• By hormone type, the estrogenic segment contributed the largest market share of 55% in the market.  This hormonal replacement therapy (ERT) has been shown to lower the risks of cardiovascular disease (CVD) and osteoporosis in postmenopausal women. Estrogen therapy helps lower the challenges of some health conditions caused by low estrogen, like osteoporosis, heart disease, dementia, and mood swings.
• By gender category, the male-to-female (MTF) segment contributed the largest market share of 60% in 2025. Individuals experiencing gender reassignment find empowerment in self-discovery and authenticity, liberation, and a renewed sense of individuality. Noteworthy relief from the distress caused by gender incongruence. This hormone therapy helps better align the body with an individual's gender identity. feminizing hormone therapy.
• By route of administration, the oral segment contributed the largest market share of 40% in 2025, as it is the most favoured route, because of its benefits, like non-invasiveness, patient compliance, and expediency of drug administration. Oral dosage forms are usually the most convenient choice. It is the simplest, most convenient, and harmless way of drug administration.
• By end user, the hospitals segment contributed the largest market share of 50% in 2025, as hospital hormone therapy for transgender and gender-fluid individuals enhances mental well-being and quality of life by more closely aligning somebody’s outer appearance with their gender identity. Hormone replacement therapy provides significant relief for a person dealing with hormonal imbalances or the indications of andropause and menopause.

Top Companies in the U.S. Sex Reassignment Hormone Therapy

The top five organizations in this group dominate the U.S. sex reassignment hormone therapy market. Meanwhile, Viatris Inc. & Pfizer Inc., a noteworthy producer of hormone therapies, including products such as DUAVEE. AbbVie Inc., its testosterone gel endures to hold an important position in the testosterone therapy. ASCEND Therapeutics US, LLC, joined with LifeMD to launch a direct-to-consumer telehealth service for hormone therapy. Halozyme Therapeutics, Inc. launched TLANDO, an oral testosterone treatment. Endo International plc. Majorly focus on restructuring and managing legacy pharmacological assets.

Segments Covered in the Report

By Hormone Type

• Estrogen
  • Oral Estrogen
  • Injectable Estrogen
  • Transdermal Estrogen
• Testosterone
  • Injectable Testosterone
  • Transdermal Testosterone
• Anti-androgens
  • Oral Anti-androgens
  • Injectable Anti-androgens

By Gender Category

• Male-to-Female (MTF)
• Female-to-Male (FTM)

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospitals
• Clinics
• Transdermal (Patch)
• Sublingual

By End User

• Hospitals
• Clinics
• Home Care 
• Others